Novartis's CEO has indicated that the delayed launch of pelabresib, a blood-cancer drug acquired through the Morphosys takeover, could occur in 2027 or later. This timeline represents a deferral from previous expectations.
Any approval for pelabresib will be contingent upon the availability and review of further safety data. This requirement introduces an element of uncertainty regarding the drug's path to market.
The delay in launching this pipeline asset impacts the anticipated revenue streams from the Morphosys acquisition. Novartis will continue to work on generating the necessary data for regulatory consideration.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.